FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898096328> ?p ?o ?g. }

• W2898096328 endingPage "134" @default.
• W2898096328 startingPage "127" @default.
• W2898096328 abstract "This study compared treatment patterns of Turkish patients with a diagnosis of rheumatoid arthritis (RA) who were treated with innovator Remicade® (infliximab [IFX]) and either continued IFX or switched to CT-P13.Adult RA patients with ≥1 IFX claim were identified from the Turkish Ministry of Health database. Eligible patients initiated and continued IFX treatment (continuers cohort [CC]) or initiated IFX and switched to CT-P13 (switchers cohort [SC]) during the study period. The initial IFX claim date was defined as the index date. The switch/reference date was defined as the CT-P13 switch date for the SC or a random IFX date during the period of CT-P13 availability for the CC. Cohorts were matched by age, sex, and number of IFX prescriptions during baseline. Patient demographics, discontinuation, and switching were summarized. The baseline period was defined as the period from the index date to the switch/reference date. The follow-up period ranged from the switch/reference date to the end of data availability.After matching, 697 patients were selected: 605 patients for the CC and 92 patients for the SC. Mean IFX duration for the baseline period was 422 days in the CC and 438 days in the SC. Median time on any infused tumor necrosis factor (TNF) antagonist therapy was 1,080 days in the CC and 540 days in the SC during the study period. During the follow-up period, discontinuation was lower in the CC (CC=33.9% vs SC=87.5%; P<0.001). The mean time to discontinuation was longer in the CC (CC=276 days vs SC=132 days; P<0.001). A switch to another biologic medication during the follow-up period was observed in 19.0% of patients in the CC (n=115) and 81.5% of patients in the SC (n=75; P<0.001).Treatment patterns differed between patients prescribed IFX and CT-P13. In Turkey, RA patients maintained on IFX had greater treatment persistence (ie, fewer and later discontinuations) than those who initiated IFX and switched to CT-P13." @default.
• W2898096328 created "2018-11-02" @default.
• W2898096328 creator A5009422030 @default.
• W2898096328 creator A5011438418 @default.
• W2898096328 creator A5020895246 @default.
• W2898096328 creator A5031805494 @default.
• W2898096328 creator A5033380416 @default.
• W2898096328 creator A5043153151 @default.
• W2898096328 creator A5065597314 @default.
• W2898096328 date "2018-10-01" @default.
• W2898096328 modified "2023-10-12" @default.
• W2898096328 title "Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab" @default.
• W2898096328 cites W1251997985 @default.
• W2898096328 cites W2017818343 @default.
• W2898096328 cites W2022888597 @default.
• W2898096328 cites W2056812338 @default.
• W2898096328 cites W2106073810 @default.
• W2898096328 cites W2146823681 @default.
• W2898096328 cites W2148487286 @default.
• W2898096328 cites W2342464058 @default.
• W2898096328 cites W2345220764 @default.
• W2898096328 cites W2521512376 @default.
• W2898096328 cites W2610308940 @default.
• W2898096328 cites W2613299853 @default.
• W2898096328 cites W2764082441 @default.
• W2898096328 cites W2766388803 @default.
• W2898096328 doi "https://doi.org/10.2147/btt.s172337" @default.
• W2898096328 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6207267" @default.
• W2898096328 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30498332" @default.
• W2898096328 hasPublicationYear "2018" @default.
• W2898096328 type Work @default.
• W2898096328 sameAs 2898096328 @default.
• W2898096328 citedByCount "11" @default.
• W2898096328 countsByYear W28980963282018 @default.
• W2898096328 countsByYear W28980963282019 @default.
• W2898096328 countsByYear W28980963282020 @default.
• W2898096328 countsByYear W28980963282021 @default.
• W2898096328 countsByYear W28980963282022 @default.
• W2898096328 countsByYear W28980963282023 @default.
• W2898096328 crossrefType "journal-article" @default.
• W2898096328 hasAuthorship W2898096328A5009422030 @default.
• W2898096328 hasAuthorship W2898096328A5011438418 @default.
• W2898096328 hasAuthorship W2898096328A5020895246 @default.
• W2898096328 hasAuthorship W2898096328A5031805494 @default.
• W2898096328 hasAuthorship W2898096328A5033380416 @default.
• W2898096328 hasAuthorship W2898096328A5043153151 @default.
• W2898096328 hasAuthorship W2898096328A5065597314 @default.
• W2898096328 hasBestOaLocation W28980963281 @default.
• W2898096328 hasConcept C126322002 @default.
• W2898096328 hasConcept C141071460 @default.
• W2898096328 hasConcept C17991360 @default.
• W2898096328 hasConcept C198451711 @default.
• W2898096328 hasConcept C2426938 @default.
• W2898096328 hasConcept C2777138892 @default.
• W2898096328 hasConcept C2777575956 @default.
• W2898096328 hasConcept C2778715236 @default.
• W2898096328 hasConcept C59491497 @default.
• W2898096328 hasConcept C71924100 @default.
• W2898096328 hasConcept C72563966 @default.
• W2898096328 hasConcept C98274493 @default.
• W2898096328 hasConceptScore W2898096328C126322002 @default.
• W2898096328 hasConceptScore W2898096328C141071460 @default.
• W2898096328 hasConceptScore W2898096328C17991360 @default.
• W2898096328 hasConceptScore W2898096328C198451711 @default.
• W2898096328 hasConceptScore W2898096328C2426938 @default.
• W2898096328 hasConceptScore W2898096328C2777138892 @default.
• W2898096328 hasConceptScore W2898096328C2777575956 @default.
• W2898096328 hasConceptScore W2898096328C2778715236 @default.
• W2898096328 hasConceptScore W2898096328C59491497 @default.
• W2898096328 hasConceptScore W2898096328C71924100 @default.
• W2898096328 hasConceptScore W2898096328C72563966 @default.
• W2898096328 hasConceptScore W2898096328C98274493 @default.
• W2898096328 hasLocation W28980963281 @default.
• W2898096328 hasLocation W28980963282 @default.
• W2898096328 hasLocation W28980963283 @default.
• W2898096328 hasLocation W28980963284 @default.
• W2898096328 hasLocation W28980963285 @default.
• W2898096328 hasOpenAccess W2898096328 @default.
• W2898096328 hasPrimaryLocation W28980963281 @default.
• W2898096328 hasRelatedWork W2109176553 @default.
• W2898096328 hasRelatedWork W2279977120 @default.
• W2898096328 hasRelatedWork W2411569365 @default.
• W2898096328 hasRelatedWork W2764082441 @default.
• W2898096328 hasRelatedWork W2786419811 @default.
• W2898096328 hasRelatedWork W2956005210 @default.
• W2898096328 hasRelatedWork W2980461776 @default.
• W2898096328 hasRelatedWork W4206985838 @default.
• W2898096328 hasRelatedWork W4253917565 @default.
• W2898096328 hasRelatedWork W646013988 @default.
• W2898096328 hasVolume "Volume 12" @default.
• W2898096328 isParatext "false" @default.
• W2898096328 isRetracted "false" @default.
• W2898096328 magId "2898096328" @default.
• W2898096328 workType "article" @default.